by The global immune checkpoint inhibitors market size was valued at US$ 31.4 billion in 2021 and is anticipated to grow US$ 148.1 billion by 2030, registering a compound annual growth rate of 18.81% from 2022 to 2030.
The immune checkpoint inhibitors market report covering various industry elements and growth trends helpful for predicting the market’s future.
The study provides a strong base for the immune checkpoint inhibitors market to be segmented into different segments. In fact, the study also covers the maximum market share during the assessment period by 2030.
This study is based on the partners that are highly competitive, key players as well as their market revenue in the forecast years of 2022 to 2030. There is also a strong focus on product revenues, sales, product categories and even the products that are experiencing the most traction. In this manner, the immune checkpoint inhibitors report also speaks about the effectiveness of this market along with its growth during the forecast period of 2030. Other major attributes of the immune checkpoint inhibitors market have been studied and analysed across many developments.
Immune Checkpoint Inhibitors Market Report Scope
| Report Coverage | Details |
| Market Size in 2022 | USD 37.31 Billion |
| Market Size by 2030 | USD 148.1 Billion |
| Growth Rate from 2022 to 2030 | CAGR of 18.81% |
| Base Year | 2021 |
| Forecast Period | 2022 to 2030 |
| Segments Covered | Drug Type, Disease Indication, End-Users, and Geography |
Also read: https://www.dailytechbulletin.com/analgesics-market/
Research Approach
The comprehensive report on the global immune checkpoint inhibitors market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products. Following this, the report provides detailed explanation of objectives of this study and laid down by accredited agencies in the purview of research in the global immune checkpoint inhibitors market.
It is followed by market introduction, market dynamics, and an overview of the global market, which includes analysis of market drivers, restraints, and trends pertaining to the global market. Furthermore, Y-o-Y growth analysis with elaborated insights has been provided in order to understand the Y-o-Y growth trend of the global market.
For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller sections. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.
Key Players are AstraZeneca PLC, Bristol-Myers Squibb Company, Eli Lilly and Company (ARMO Biosciences.), GlaxoSmithKline PLC, Roche Holding AG, Incyte Corporation, Novartis AG, F. Hoffmann-La Roche Ltd. (Genentech Inc.,), Sanofi, Merck & Co., Inc., Merck KGaA (EMD Serono Inc.), BeiGene Ltd, Shanghai Jhunsi Biosciences Ltd.
Immune Checkpoint Inhibitors Market Segmentations
By Drug Type
- CTLA-4 Inhibitor
- PD-1 Inhibitor
- PD-L1 Inhibitor
By Disease Indication
- Lung Cancer
- Bladder Cancer
- Melanoma
- Hodgkin lymphoma
- Others
By End-Users
- Hospitals
- Specialty Clinics
- Academic & Research Institutions
By Geography
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East & Africa (MEA)
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Immune Checkpoint Inhibitors Market
5.1. COVID-19 Landscape: Immune Checkpoint Inhibitors Industry Impact
5.2. COVID 19 – Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Immune Checkpoint Inhibitors Market, By Drug Type
8.1. Immune Checkpoint Inhibitors Market, by Drug Type, 2022-2030
8.1.1 CTLA-4 Inhibitor
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. PD-1 Inhibitor
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. PD-L1 Inhibitor
8.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Immune Checkpoint Inhibitors Market, By Disease Indication
9.1. Immune Checkpoint Inhibitors Market, by Disease Indication, 2022-2030
9.1.1. Lung Cancer
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Bladder Cancer
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Melanoma
9.1.3.1. Market Revenue and Forecast (2017-2030)
9.1.4. Hodgkin lymphoma
9.1.4.1. Market Revenue and Forecast (2017-2030)
9.1.5. Others
9.1.5.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Immune Checkpoint Inhibitors Market, By End-Users
10.1. Immune Checkpoint Inhibitors Market, by End-Users, 2022-2030
10.1.1. Hospitals
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Specialty Clinics
10.1.2.1. Market Revenue and Forecast (2017-2030)
10.1.3. Academic & Research Institutions
10.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 11. Global Immune Checkpoint Inhibitors Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Drug Type (2017-2030)
11.1.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
11.1.3. Market Revenue and Forecast, by End-Users (2017-2030)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Drug Type (2017-2030)
11.1.4.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
11.1.4.3. Market Revenue and Forecast, by End-Users (2017-2030)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Drug Type (2017-2030)
11.1.5.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
11.1.5.3. Market Revenue and Forecast, by End-Users (2017-2030)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Drug Type (2017-2030)
11.2.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
11.2.3. Market Revenue and Forecast, by End-Users (2017-2030)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Drug Type (2017-2030)
11.2.4.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
11.2.4.3. Market Revenue and Forecast, by End-Users (2017-2030)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Drug Type (2017-2030)
11.2.5.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
11.2.5.3. Market Revenue and Forecast, by End-Users (2017-2030)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Drug Type (2017-2030)
11.2.6.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
11.2.6.3. Market Revenue and Forecast, by End-Users (2017-2030)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Drug Type (2017-2030)
11.2.7.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
11.2.7.3. Market Revenue and Forecast, by End-Users (2017-2030)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Drug Type (2017-2030)
11.3.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
11.3.3. Market Revenue and Forecast, by End-Users (2017-2030)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Drug Type (2017-2030)
11.3.4.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
11.3.4.3. Market Revenue and Forecast, by End-Users (2017-2030)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Drug Type (2017-2030)
11.3.5.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
11.3.5.3. Market Revenue and Forecast, by End-Users (2017-2030)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Drug Type (2017-2030)
11.3.6.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
11.3.6.3. Market Revenue and Forecast, by End-Users (2017-2030)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Drug Type (2017-2030)
11.3.7.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
11.3.7.3. Market Revenue and Forecast, by End-Users (2017-2030)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Drug Type (2017-2030)
11.4.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
11.4.3. Market Revenue and Forecast, by End-Users (2017-2030)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Drug Type (2017-2030)
11.4.4.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
11.4.4.3. Market Revenue and Forecast, by End-Users (2017-2030)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Drug Type (2017-2030)
11.4.5.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
11.4.5.3. Market Revenue and Forecast, by End-Users (2017-2030)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Drug Type (2017-2030)
11.4.6.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
11.4.6.3. Market Revenue and Forecast, by End-Users (2017-2030)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Drug Type (2017-2030)
11.4.7.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
11.4.7.3. Market Revenue and Forecast, by End-Users (2017-2030)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Drug Type (2017-2030)
11.5.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
11.5.3. Market Revenue and Forecast, by End-Users (2017-2030)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Drug Type (2017-2030)
11.5.4.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
11.5.4.3. Market Revenue and Forecast, by End-Users (2017-2030)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Drug Type (2017-2030)
11.5.5.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
11.5.5.3. Market Revenue and Forecast, by End-Users (2017-2030)
Chapter 12. Company Profiles
12.1. AstraZeneca PLC
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Bristol-Myers Squibb Company
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Eli Lilly and Company (ARMO Biosciences.)
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. GlaxoSmithKline PLC
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Roche Holding AG
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Incyte Corporation
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Novartis AG
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. F. Hoffmann-La Roche Ltd. (Genentech Inc.,)
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Sanofi, Merck & Co., Inc.
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Merck KGaA (EMD Serono Inc.)
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Why should you invest in this report?
If you are aiming to enter the global immune checkpoint inhibitors market, this report is a comprehensive guide that provides crystal clear insights into this niche market. All the major application areas for immune checkpoint inhibitors are covered in this report and information is given on the important regions of the world where this market is likely to boom during the forecast period of 2022-2030 so that you can plan your strategies to enter this market accordingly.
Besides, through this report, you can have a complete grasp of the level of competition you will be facing in this hugely competitive market and if you are an established player in this market already, this report will help you gauge the strategies that your competitors have adopted to stay as market leaders in this market. For new entrants to this market, the voluminous data provided in this report is invaluable.
Request a Sample Copy of This Report @ https://www.precedenceresearch.com/sample/2281
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
